# A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

> **NCT02296801** · PHASE2 · COMPLETED · sponsor: **NSABP Foundation Inc** · enrollment: 307 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Breast Tumors

## Interventions

- **DRUG:** Letrozole
- **DRUG:** palbociclib

## Key facts

- **NCT ID:** NCT02296801
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-07
- **Final completion:** 2019-03
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2022-01-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296801, "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02296801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*